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Abstract
Background: Since non-tuberculous mycobacteria (NTM) disease is not notifiable in most European Union (EU) and
European Economic Area (EEA) countries, the epidemiological situation of the >150 NTM species is largely
unknown. We aimed to collect data on the frequency of NTM detection and NTM species types in EU/EEA
countries.
Methods: Officially nominated national tuberculosis reference laboratories of all EU/EEA countries were asked to
provide information on: laboratory routines for detection and identification of NTM, including drug sensitivity
testing (DST) methods; data on the number and type of NTM species identified; coverage and completeness of the
provided data on NTM; type and number of human specimens tested for NTM; and number of specimens tested
for Mycobacterium tuberculosis complex and NTM. This information was summarized and the main results are
described.
Results: In total, 99 different NTM species were identified with M. avium, M. gordonae, M. xenopi , M. intracellulare,
and M. fortuitum identified most frequently. Seven percent of the NTM species could not be identified. NTM was
cultured from between 0.4-2.0% of the specimens (data from four countries). The laboratories use culturing
methods optimised for M. tuberculosis complex. Identification is mainly carried out by a commercial line probe
assay supplemented with sequencing. Most laboratories carried out DST for rapid growers and only at the explicit
clinical request for slow growers.
Conclusion: It is likely that the prevalence of NTM is underestimated because diagnostic procedures are not
optimized specifically for NTM and isolates may not be referred to the national reference laboratory for identification.
Due to the diagnostic challenges and the need to establish the clinical relevance of NTM, we recommend that countries
should concentrate detection and identification in only few laboratories.
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Background
Today, more than 150 non-tuberculous mycobacteria
(NTM) species have been described [1-3]. Many have only
been described after the introduction of molecular methods
in the 1990’ies and still quite a number of NTM remain un-
classified. NTMs are capable of causing disease, but the
pathogenicity varies among the species [4]. In general, it is a
challenge to identify NTM species as the specific causal
agent of disease, especially because recovery of NTM from a
culture of a respiratory specimen may be due to contamin-
ation of the specimen or transient colonization of the pa-
tient. Therefore the clinical significance of detected NTM in
non-sterile specimens needs to be evaluated for the individ-
ual patient, which is usually done according to the guidelines
from the American Thoracic Society (ATS) [5].
So far, there is very limited evidence for person-to-
person transmission of NTM [1,6,7]. Outbreaks caused
by exposure to the same reservoir have been described
[8]. It is generally accepted that a wide range of animal
and environmental sources (swimming pools, aquaria)
are reservoirs for NTM. Examples include marine animals
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for Mycobacterium marinum, tap waters and potting for
M. avium complex, and tap water for M. gordonae. NTM
species have also been detected in medical devices in
hospital settings [9] and can therefore pose a risk to vulner-
able hospitalized patients. For most species, no single res-
ervoir has been identified.
Although it is a challenge to link NTM to disease in
man, significant NTM disease has been described among
patients suffering from cystic fibrosis (often with M.
abscessus) [7], chronic obstructive pulmonary disease
(COPD) [10], HIV and other immunosuppressive condi-
tions [11], and in otherwise healthy children having cer-
vical NTM lymph adenitis [12]. In addition, inhaled
corticosteroids [13] and TNF-a inhibitor treatment
[14,15] are associated with NTM disease. Host factors
such as IL-12 deficiency has been described among other
genetic host factors [16]. NTM infections are most fre-
quently located in the lungs, but may also be found in
lymph nodes, skin, soft tissue, and joint and bones, and
can be disseminated [17].
NTM disease is not notifiable in most countries.
Therefore, the overall epidemiological situation of NTM
in the European Union (EU) and European Economic
Area (EEA) is largely unknown. Several EU countries
have published reports about the situation in their coun-
try [18]. In England, Wales and Northern Ireland an in-
crease in NTM was reported [19]. A report from
Portugal found a high percentage of NTM strains among
mycobacterial isolates [20]. A multi country overview
that included information from EU/EEA countries with
data up to 1996 was published by the Working Group of
the Bacteriology and Immunology Section of the Inter-
national Union Against Tuberculosis and Lung Disease
[21]. This study concluded that there was an increase in
the number of NTM isolated from clinical samples of
patients. A recently published snapshot of NTM in pul-
monary samples collected in 2008 in 30 different coun-
tries from different continents showed that M. avium
complex (MAC) bacteria predominated in most coun-
tries, followed by M. gordonae and M. xenopi [22].
The aim of the present study was to provide an over-
view on the frequency of NTM detection and the types
of NTM species detected in EU/EEA countries. In
addition, an overview of the laboratory methods used for
detection and identification of NTM in EU/EEA coun-
tries is given.
Methods
We invited all EU/EEA countries to participate in this
inventory by contacting the European Centre for Disease
Prevention and Control (ECDC) national TB reference
laboratory contact points in August 2012. Countries
were asked to provide information on: laboratory rou-
tines for detection and identification of NTM, including
drug sensitivity testing (DST) methods; data on the
number and type of NTM species identified in pulmon-
ary as well as non-pulmonary specimens; coverage and
completeness of the provided data on NTM; type and
number of human specimens tested for NTM; and num-
ber of specimens tested for Mycobacterium tuberculosis
complex and NTM.
The provided information was summarized in tables
and the main results are described.
Results
Ten EU countries, Croatia, Denmark, Estonia, Finland,
Germany, Greece, Italy, Luxembourg, Netherlands,
Slovenia, provided data for the inventory study on NTM
(Table 1). In 6 countries (Croatia, Denmark, Estonia,
Finland, Luxembourg, Slovenia), the NTM data are con-
sidered to be complete for the country. In Greece and
the Netherlands, the data are considered almost
complete, and in Italy the data are complete for a part of
the country. The National Reference Laboratory of
Germany only receives a fraction of the NTM samples
and thus the data are incomplete. Finland is the only
participating country in which notification of NTM is
mandatory. The data in Table 2 refer to positive specimens
for Croatia, Estonia, Germany, Greece, Luxembourg and
Slovenia, whereas for Denmark, Finland, Italy and the
Netherlands the data refer to patients with NTM.
In most countries NTM are detected by smear micros-
copy and by both solid and liquid culture (Table 1). In
Denmark, in Finland in one clinical laboratory, and in
Luxembourg PCR is used for detection. In Germany
PCR is used on special request and in the Netherlands
PCR is used by specific laboratories. Denmark, Croatia,
Estonia, Finland, Germany, Italy, Luxembourg, the
Netherlands, and Slovenia reported to incubate some
types of specimens (for example skin and lymph node
samples, and sputum from cystic fibrosis patients) at a
lower temperature, i.e. 30-32°C. The GenoType Myco-
bacterium CM/AS (Hain Lifescience, Nehren, Germany)
was the most frequent used method for identification of
NTM species. Many countries also used sequencing to
identify species. Different methods were used for deter-
mining the drug sensitivity of the NTM species and
often DST was only performed at specific request of a
clinician.
M. avium, M. gordonae, M. xenopi , M. intracellulare,
and M. fortuitum were detected most frequently overall
(Table 2). These species account for two thirds of all
identified species. Almost 7% of the isolates could not be
identified as an officially recognised species. The rest of
the isolates were distributed over 94 species - of which
many were observed very infrequently.
The order of the most frequently reported species
changes slightly if only data from the four countries that
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Table 1 Detection, identification and drug sensitivity testing procedures for non-tuberculous mycobacteria (NTM) in 10
European Union countries
Country Detection NTM Identification NTM Drug sensitivity testing
Croatia Smear microscopy and culture on solid and
liquid media
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany)
supplemented with phenotypic analysis
including examination of growth
characteristics, temperature tolerance,
pigmentation and biochemical properties
For rapidly growing species* by E-test (AB
Biodisk, Solna, Sweden) strips or minimum
inhibitory concentration (MIC) testing.
Denmark Smear microscopy, culture on solid
(Löwenstein-Jensen) and liquid media (BD
Bactec MGIT 960) and PCR
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany) supplemented
by 16S rDNA sequencing and/or other
methods
For rapid growing species: MIC
determination on TREK microwell plates
(TREK Diagnostic Systems, Cleveland, Ohio,
United States of America). For slow growing
species only at specific request of clinician
Estonia Smear microscopy, culture on solid media
(e.g. Löwenstein-Jensen) and liquid media
(BD Bactec MGIT 960)
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany)
Not performed
Finland Culture on solid media (e.g. Löwenstein-
Jensen or Middlebrook 7H11) and liquid
media (BD Bactec MGIT 960)
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany) and, if
needed, 16S rDNA sequencing
For species belonging to M. avium
complex (MAC): narrow range MIC
method for azithromycin, clarithromycin,
ethambutol, clofatzimin, and rifabutin. For
rapid growing species belonging to the M.
chelonae-fortuitum complex: E-test (Bio-
Merieux, Lyon, France)
Germany Smear microscopy and culture on solid and
liquid media, and for certain specimens
(skin, lymph nodes, sputum from CF
patients) incubation on specific media at
lower temperatures (31°C)
Line probe assays or sequence analysis
(16S rDNA, ITS, rpoB)
Slowly growing species: modified
proportion method using MGIT liquid
media (BACTEC MGIT 960 or manual
system). Drugs tested comprise first line TB
drugs as well as clarithromycin or on
special request fluoroquinolones. For other
slow growing species, i.e. M. avium/
intracellulare: A combination of drugs is
applied for DST testing
Greece Smear microscopy and culture on solid and
liquid media
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany) and when
requested by the clinicians, 16S rDNA and
hsp65 gene sequencing
For slow growing species, the modified
proportion method using BACTEC MGIT
960 or LJ is applied. First line anti-TB drugs
and clarithromycin are tested according to
ATS/ IDSA guidelines [5]. On special
request FQs are also tested. For rapid
growing species, MIC testing on microwell
plates is performed (TREK Diagnostic
Systems, Cleveland, Ohio, United States of
America).
Italy Culture on solid (Löwenstein-Jensen) and
liquid media (BD Bactec MGIT 960)
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany) and sequencing
of genetic regions (16S rRNA and/or hsp65
genes for slow growers, rpoB gene for rapid
growers, ITS1 for members of MAC) whenever
the commercially available molecular probes
(Genotype CM and AS) produced an
identification known to be not 100% free from
cross reactions with other species
For rapid growing species: MIC
determination (Rapidly growing
mycobacteria panel, TREK Diagnostic
Systems (Cleveland, Ohio, United States of
America). For slow growing species:
susceptibility to chlarithromycin is
determined for some cases.
Luxembourg Culture on solid (Lowenstein Jensen,
Coletsos and Middlebrook 7H11) and liquid
media (BD Bactec MGIT 960)
To distinguish MTB complex from NTM
isolates the Anyplex MTB/NTM Real Time
detection kit (Seegene) is used. In a second
stage, NTM specimens are sequenced
(sequencing of the hsp65 gene)
Not performed in country. On explicit
request of the doctor, the isolate is sent to
the Belgian Scientific Institute for Public
Health
Netherlands Culture on liquid media (BD Bactec MGIT
960)
Commercially available reverse line blot
assays
7H10 agar dilution method [23] for both
slow and rapid growing species
Slovenia Culture on solid and liquid media. Some
clinical samples are incubated at 30°C and
on media with special supplements.
GenoType Mycobacterium CM/AS (Hain
Lifescience, Nehren, Germany), colony
morphology on transparent medium
Middlebrook 7H10, and some phenotypic
tests
At specific request of clinician for rapid
growing species and some slow growing
species: E-test (AB Biodisk, Solna, Sweden)
*For definition of slow growing and rapidly growing species see reference [24].
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Table 2 Species distribution of non-tuberculous mycobacteria isolated in 10 European Union countries
Species*
Country Total
Croatia
(2008-
2010)
Denmark
(2011)
Estonia
(2004-
2011)
Finland
(1995-
2011)
Germany
(2011)
Greece
(2005-
2011)
Italy
(2001-
2010)
Luxembourg
(2009-
2011)
Netherlands
(2006-
2011)
Slovenia
(2000-
2010)
M. avium 33 86 308 1,568 176 101 350 23 1,274 349 4,268
M. gordonae 377 9 96 1,286 176 31 253 26 623 365 3,242
M. xenopi 122 7 12 13 9 687 13 77 615 1,555
M. intracellulare 23 15 52 636 272 49 104 3 359 156 1,669
M. fortuitum 98 2 65 521 68 66 144 239 150 1,353
M. kansasii 8 5 11 53 58 22 39 6 283 181 666
M. chelonae 31 3 20 179 56 37 55 4 173 32 590
M. abscessus 25 10 17 94 37 17 111 11 228 24 574
M. malmoense 12 14 184 10 7 11 6 108 22 374
M. lentiflavum 6 5 246 4 6 45 5 317
M. marinum 7 3 50 29 5 15 4 115 6 234
M. terrae 52 151 16 6 225
M. peregrinum 9 3 15 81 20 33 1 6 168
M. simiae 3 69 5 21 3 64 165
M. bohemicum 106 1 4 3 10 124
M. chimaera 48 5 68 121
M. interjectum 1 3 87 6 9 14 120
M.
nonchromogenicum
18 38 1 41 1 21 120
M. arupense 7 83 3 8 101
M. celatum 3 7 1 3 8 12 1 11 21 67
M. mucogenicum 3 6 38 15 62
M. scrofulaceum 2 16 12 12 12 54
M. szulgai 2 3 13 11 17 6 52
M. kumamotonense 1 46 1 48
M. heraklionense 46 46
M. genavense 8 5 18 31
M. phlei 4 7 3 13 27
M. vulneris 26 1 27
M. haemophilum 1 1 18 20
M. triviale 15 2 17
M. arosiense 15 15
M. florentinum 1 6 5 12
M. nebraskense 11 1 12
M. neoaurum 3 5 4 12
M. vaccae 10 1 11
M. elephantis 10 10
M. insubricum 1 8 9
M.
parascrofulaceum
4 5 9
M. sherrisii 9 9
M. alvei 2 6 8
M. porcinum 5 2 1 8
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Table 2 Species distribution of non-tuberculous mycobacteria isolated in 10 European Union countries (Continued)
M. europaeum 3 4 7
M. flavescens 6 1 7
M. shimoidei 4 3 7
M. gilvum 6 6
M. longobardum 6 6
M. paraffinicum 1 4 1 6
M. triplex 6 6
M. branderi 1 1 3 5
M. goodii 1 1 3 5
M. holsaticum 2 2 1 5
M. smegmatis 4 1 5
M. thermoresistibile 1 4 5
M. cosmeticum 1 3 4
M. heckeshornense 1 1 1 1 4
M. agri 1 2 3
M. brumae 2 1 3
M. flavescens/ M.
novocastrense
3 3
M. frederiksbergense 3 3
M. hassiacum 1 2 3
M. heidelbergense 1 2 3
M. lepraemurium 3 3
M. mantenii 2 1 3
M. noviomagense 1 2 3
M. palustre 3 3
M. setense 3 3
M. wolinskyi 1 2 3
M. aichiense 2 2
M. engbaekii 2 2
M. gastri 2 2
M. immunogenum 2 2
M. intermedium 2 2
M. llatzerense 2 2
M. mageritense 2 2
M. monacense 2 2
M. novocastrense 1 1 2
M. phocaicum 1 1 2
M. pulveris 2 2
M. rhodesiae 2 2
M. riyadhense 1 1 2
M. asiaticum 1 1
M. aubagnense 1 1
M.
chlorophenolicum
1 1
M. colombiense 1 1
M. conceptionense 1 1
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report NTM in patients were taken into account, i.e. M.
avium, M. gordonae, M. intracellulare, M. fortuitum,
and M. xenopi.
In Table 2 we show all data provided by the participat-
ing countries. Some countries provided data for 1 year
only, while others provide data for up to 17 years
(Finland). To give each country equal weight we calcu-
lated the average number of species per year for coun-
tries that provided data for more than one year (data not
shown). This weighing procedure did not change the top
five most frequent species. It did change the order
slightly into M. avium, M. gordonae, M. fortuitum, M.
xenopi, and M. intracellulare.
NTM were detected from a variety of clinical speci-
mens as demonstrated by data from Croatia, Italy,
Luxembourg and Slovenia in Table 3. Both sterile and
non-sterile specimens were reported NTM culture posi-
tive. A high number of pulmonary specimens are found
NTM culture positive, but this likely reflects the fact
that these specimens are submitted for culture more fre-
quently compared to other specimens.
Five countries provided information on the number of
specimens tested and the frequency of M. tuberculosis
complex and NTM isolation (Table 4). Between 2.8 and
11.3% of all tested specimens were positive for M. tuber-
culosis complex. Whereas only between 0.4 and 2.0%
tested positive for NTM.
Discussion
NTM disease and detection is not notifiable in most EU/
EEA countries and therefore high quality information is
not readily available. In the countries that participated in
the inventory, the national TB reference laboratories
often have a good overview of the frequency of detection
of NTM and the distribution of mycobacterial isolates
over the different species. The reported data show that
M. avium, M. gordonae, M. xenopi, M. intracellulare, and
M. fortuitum are isolated most frequently and that ap-
proximately 7% of all isolates cannot be identified as valid
species.
Table 2 Species distribution of non-tuberculous mycobacteria isolated in 10 European Union countries (Continued)
M. conspicuum 1 1
M. duvalii 1 1
M.
fluoroanthenivorans
1 1
M. gadium 1 1
M. hiberniae 1 1
M. kyorinense 1 1
M. massiliense 1 1
M. parmense 1 1
M. poriferae 1 1
M. senegalense 1 1
M. senuense 1 1
M. timonense 1 1
M. tokaiense 1 1
M. tusciae 1 1
Unknown 8 57 429# 41 48 96 2 186 279 717
Total 848 182 698 5,778 1,068 426 2,498 123 3,996 2,240 17,857
*Croatia, Estonia, Germany, Greece, Luxembourg and Slovenia report positive specimens, Denmark, Finland, Italy and the Netherlands report patients with NTM.
#Unknown species and rare species.
Table 3 Specimen types from which non-tuberculous
mycobacteria were isolated*
Specimen type Number of specimen positive for NTM
Sputum 2,839
Other pulmonary 1,160
Bronchial aspirate 191
Urine 117
Biopsy 74
Blood 47
Stool 45
Other body fluid 28
Gastric lavage 22
Lymph node aspiration 20
Pleural fluid 14
Cutis 8
Cerebrospinal fluid 3
Not specified 2,276
*Data from Croatia, Italy, Luxembourg and Slovenia.
van der Werf et al. BMC Infectious Diseases 2014, 14:62 Page 6 of 9
http://www.biomedcentral.com/1471-2334/14/62
In most countries included in this inventory, only few
laboratories are performing isolation and identification of
NTM. This allows for high quality and standardization of
species identification. However, together with the fact
that clinical and laboratory diagnosis of NTM is challen-
ging it might result in an underestimation of the true
prevalence of NTM because samples/isolates need to be
send from the laboratory that performed the initial diag-
nostic test to the laboratory that is able to do the species
identification.
The aim of this inventory study was to collect and
present available data from national TB reference labora-
tories on NTM. We did not prescribe by which methods
NTM needed to be isolated and identified and also the
year of isolation and population were not specified. It
would be interesting to use uniform diagnostic methods,
sample population and period of sample collection to be
able to compare the prevalence and frequency of NTM
in different countries.
Since participation in the inventory was voluntary only
part of the EU countries participated, probably countries
that have information on NTM available. The 10 coun-
tries that participated are located in different parts of
the EU, both the North and the South, and also the
West and the East. Assuming that the distribution of
NTM will not be affected by national borders but by
geographical location, the frequency of detection of
NTM might well be representative for the EU.
Based on Croatian, Estonian, Greek, Luxembourgish
and Slovenian data, NTM was cultured from between
0.4-2.0% of the specimens. As it can be very difficult to
discriminate NTM disease from TB based on symptoms
and clinical findings, specimens are usually submitted
for culture of mycobacteria in general. The laboratories
use methods optimised for detection of M. tuberculosis
complex also for culturing of NTM in general with a
few exceptions. Both the difficulty in discriminating
NTM disease from TB clinically and the fact that it is
impossible to optimise specimen pre-treatment and in-
cubation for more than >150 different NTM species
makes this is a reasonable routine that may - however -
underestimate NTM. Some patients, such as patients suf-
fering from cystic fibrosis, can be expected to be infected
with a certain species (M. abscessus) and pre-treatment
of specimens optimizing isolation of this species can
therefore be a good strategy to improve detection [25].
Specific elements of an optimal testing algorithm for M.
tuberculosis complex as well as all non-tuberculous
mycobacteria need to be identified and comparison with
current routines needs to be carried out.
Identification of NTM is mainly carried out by a com-
mercial line probe assay supplemented with sequencing.
The use of the same commercial method in many coun-
tries may help standardisation of NTM identification
and supports comparison of results between countries,
but it also creates some vulnerability in case of quality
problems of the commercial kit [26]. For NTM identifi-
cation, however, this is a minor problem as long as M.
tuberculosis can be excluded rapidly and sequencing can
be applied.
Seven percent of all NTM isolates could not be recog-
nised as valid species. This group actually consists of two
distinct groups, depending on the laboratory were the
identification was performed. In laboratories using com-
mercial DNA probes this group consists of all strains that
cannot be identified by commercial DNA probes. In
other laboratories this group consists of species that had
not yet been recognized as validly described species at
the moment of identification. Some species may not be
so rare if the commercial identification methods would
allow for identification. Thus, new methods for identifi-
cation are needed. Using additional methods for identifi-
cation, the Netherlands recently described the distinction
between M. noviomagense and M. xenopi, to which it is
closely related [27]. M. xenopi is clinically significant in a
high percentage of the patients whereas M. noviomagense
has never been associated with NTM disease. Therefore,
such a more fine-tuned distinction serves both the clin-
ician and the patient. Whole Genome Sequencing (WGS)
will probably facilitate an improved taxonomy of NTM
in the future.
Even though NTMs do not seem to be very transmis-
sible from person to person, especially in immune-
competent persons, and outbreaks are infrequent,
information on the frequency of the disease is useful, es-
pecially because the EU/EEA population is aging and
more persons may suffer from chronic disease and pos-
sible immunosuppression and therefore be at risk for
NTM disease. Risk groups for pulmonary NTM disease
include patients with COPD, bronchiectasis, previous
TB, and those using corticosteroids [13] or undergoing
organ transplant [8]. A specific risk groups for pulmon-
ary NTM disease with M. abscessus are cystic fibrosis
patients [28].
Table 4 Number of specimens tested and specimens
positive for M. tuberculosis complex and non-tuberculous
mycobacteria (NTM) in Estonia, Greece, Croatia,
Luxembourg, and Slovenia
Country Specimens
tested, N
Specimens positive
for M. tuberculosis
complex, N (%)
Specimen positive
for NTM, N (%)
Croatia 166,561 8,375 (5.0) 848 (0.5)
Estonia 83,655 9,475 (11.3) 698 (0.8)
Greece 114,106 3,194 (2.8) 426 (0.4)
Luxembourg 6,113 277 (4.5) 123 (2.0)
Slovenia 148,744 11,368 (7.6) 2,240 (1.5)
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Often the clinical significance of isolation of NTM from
non-sterile specimens such as sputum is uncertain, and
the clinical, radiography and microbiology criteria of the
American Thoracic Society (ATS) are applied to come to
a conclusion about the necessity of treatment [5]. A retro-
spective review of patient files in the Netherlands led to
the conclusion that the clinical relevance differed signifi-
cantly by NTM species [29]. For instance, in most cases
where M. szulgai was isolated, treatment was needed. In
contrast, isolation of M. gordonae was hardly ever
clinically relevant. Tortoli and Koh also emphasized
that NTM species differ in their ability to cause lung
disease in humans [30,31] and found that M. kansasii,
M. malmoense, M. szulgai and M. shimoidei, which
are considered more pathogenic than other NTMs,
accounted, as a whole, for 1.1% of the isolates. The
number of cases in which M. xenopi was responsible
for severe pulmonary disease, although difficult to
quantify, was however considerable, which is in agree-
ment with findings from Denmark that 51% of pa-
tients with M. xenopi detected are dead after 5 years
[32]. In our study, we collected information about fre-
quency of NTM isolation from laboratories in the
participating countries. The collected information
does not inform whether the patients from which the
specimens were collected fulfilled the clinical, radiog-
raphy and microbiology criteria of the ATS.
Drug susceptibility testing has been standardized for
rapid growers and few slowly growing species [33]. A ma-
jority of laboratories in this study, carried out DST for
rapid growers by either E-test or TREK microbroth dilu-
tion. For slowly growing species, a variety of methods
were applied. Often DST was carried out only after spe-
cific request of the clinician. For many species, questions
regarding the correlation between DST results and treat-
ment response remain to be addressed.
Conclusion
There is likely an under reporting of NTM because it is
not notifiable, and in most countries samples/isolates
need to be send to the reference laboratory for detection
and/or identification of NTM. Also, diagnostic proce-
dures are not optimized for isolation of the different
NTM species. Since risk groups that are more prone to
NTM disease are growing, it is recommended to system-
atically collect laboratory information and some basic
epidemiological data to monitor NTM at country level.
Due to the large number of different NTM species
and the challenge in identification and in establishing
the clinical relevance countries should concentrate the
diagnosis and species identification in one or few labora-
tories. Laboratory experts from should be available for
consultation by the clinicians about the interpretation of
the laboratory result.
Abbreviations
ATS: American thoracic society; COPD: Chronic obstructive pulmonary
disease; DST: Drug sensitivity testing; ECDC: European centre for disease
prevention and control; EEA: European economic area; EU: European Union;
MAC: Mycobacterium avium complex; MIC: Minimum inhibitory
concentration; NTM: Non tuberculous mycobacteria.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MW conceived of the study, participated in the design and coordination,
and drafted and revised the manuscript. CK participated in the design and
coordination and helped to draft the tables. VKJ, TK, HS, ER, DP, ET, MP, DS,
and MZD provided data, reviewed the draft manuscript, and have given final
approval of the version to be published. VØT conceived of the study,
participated in the design and coordination, provided data and helped to
draft the manuscript. All authors read and approved the final manuscript.
Author details
1European Centre for Disease Prevention and Control, Stockholm, Sweden.
2National Mycobacterium Reference Laboratory, Croatian National Institute of
Public Health, Zagreb, Croatia. 3Department of Mycobacteriology, Tartu
University Hospital, Tartu, Estonia. 4National Institute for Health and Welfare,
Turku, Finland. 5National Reference Laboratory for Mycobacteria,
Forschungszentrum Borstel, Borstel, Germany. 6National Reference Laboratory
for Mycobacteria, “Sotiria” Chest Diseases Hospital, Athens, Greece. 7Emerging
Bacterial Pathogens Unit, San Raffaele Scientific Institute, Milan, Italy. 8Division
de Bactériologie – Parasitologie, Laboratoire National de Santé, Luxembourg,
Luxembourg. 9National Institute for Public Health and the Environment
(RIVM), Bilthoven, The Netherlands. 10National Reference Laboratory for
Mycobacteria, University Clinic of Respiratory and Allergic Diseases, Golnik,
Slovenia. 11International Reference Laboratory of Mycobacteriology, Statens
Serum Institut, Copenhagen, Denmark.
Received: 28 August 2013 Accepted: 22 November 2013
Published: 6 February 2014
References
1. Piersimoni C, Scarparo C: Pulmonary infections associated with non-
tuberculous mycobacteria in immunocompetent patients. Lancet Infect
Dis 2008, 8(5):323–334.
2. Daley CL, Griffith DE: Pulmonary non-tuberculous mycobacterial
infections. Int J Tuberc Lung Dis 2010, 14(6):665–671.
3. List of prokaryotic names with standing in nomenclature - genus.
Mycobacterium. http://www.bacterio.net/index.html.
4. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree
MJ, van Soolingen D: Clinical relevance of non-tuberculous mycobacteria
isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009,
64(6):502–506.
5. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F,
Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al: An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367–416.
6. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher
M, Haworth CS, Curran MD, Harris SR, et al: Whole-genome sequencing to
identify transmission of mycobacterium abscessus between patients
with cystic fibrosis: a retrospective cohort study. Lancet 2013,
381(9877):1551–1560.
7. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR,
Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, et al: Respiratory
outbreak of mycobacterium abscessus subspecies massiliense in a lung
transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012,
185(2):231–232.
8. Padoveze MC, Fortaleza CM, Freire MP, Brandao de Assis D, Madalosso G,
Pellini AC, Cesar ML, Pisani Neto V, Beltramelli MM, Chimara E, et al:
Outbreak of surgical infection caused by non-tuberculous mycobacteria
in breast implants in Brazil. J Hosp Infect 2007, 67(2):161–167.
9. Lowry PW, Beck-Sague CM, Bland LA, Aguero SM, Arduino MJ, Minuth AN,
Murray RA, Swenson JM, Jarvis WR: Mycobacterium chelonae infection
van der Werf et al. BMC Infectious Diseases 2014, 14:62 Page 8 of 9
http://www.biomedcentral.com/1471-2334/14/62
among patients receiving high-flux dialysis in a hemodialysis clinic in
California. J Infect Dis 1990, 161(1):85–90.
10. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Jarvinen A: Clinical
symptoms and survival in non-smoking and smoking HIV-negative
patients with non-tuberculous mycobacterial isolation. Scand J Infect Dis
2011, 43(3):188–196.
11. Hoefsloot W, van Ingen J, Peters EJ, Magis-Escurra C, Dekhuijzen PN, Boeree
MJ, van Soolingen D: Mycobacterium genavense in the Netherlands: an
opportunistic pathogen in HIV and non-HIV immunocompromised
patients. An observational study in 14 cases. Clin Microbiol Infect 2012,
19(5):432–437.
12. Ding LW, Lai CC, Lee LN, Huang LM, Hsueh PR: Lymphadenitis caused by
non-tuberculous mycobacteria in a university hospital in Taiwan:
predominance of rapidly growing mycobacteria and high recurrence
rate. J Formos Med Assoc 2005, 104(12):897–904.
13. Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW:
Chronic respiratory disease, inhaled corticosteroids and risk of non-
tuberculous mycobacteriosis. Thorax 2012, 68(3):256–262.
14. Kluger N, Cohen P, Fallet-Bianco C, Guillevin L: Mycobacterium chelonae
infection under adalimumab therapy for spondylarthritis. Clin Exp
Rheumatol 2010, 28(1):101–102.
15. Maimon N, Brunton J, Chan AK, Marras TK: Fatal pulmonary
mycobacterium xenopi in a patient with rheumatoid arthritis receiving
etanercept. Thorax 2007, 62(8):739–740.
16. van de Vosse E, Hoeve MA, Ottenhoff TH: Human genetics of intracellular
infectious diseases: molecular and cellular immunity against
mycobacteria and salmonellae. Lancet Infect Dis 2004, 4(12):739–749.
17. Thomsen VO, Andersen AB, Miorner H: Incidence and clinical significance
of non-tuberculous mycobacteria isolated from clinical specimens during
a 2-y nationwide survey. Scand J Infect Dis 2002, 34(9):648–653.
18. Ringshausen FC, Apel RM, Bange FC, de Roux A, Pletz MW, Rademacher J,
Suhling H, Wagner D, Welte T: Burden and trends of hospitalisations
associated with pulmonary non-tuberculous mycobacterial infections in
Germany, 2005-2011. BMC Infect Dis 2013, 13:231.
19. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I: Increasing
reports of non-tuberculous mycobacteria in England, Wales and
Northern Ireland, 1995-2006. BMC Public Health 2010, 10:612.
20. Amorim A, Macedo R, Lopes A, Rodrigues I, Pereira E: Non-tuberculous
mycobacteria in HIV-negative patients with pulmonary disease in Lisbon,
Portugal. Scand J Infect Dis 2010, 42(8):626–628.
21. Martin-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M,
Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Koksalan K, et al:
Non-tuberculous mycobacteria: patterns of isolation. A multi-country
retrospective survey. Int J Tuberc Lung Dis 2004, 8(10):1186–1193.
22. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis
N, Boeree MJ, Cacho J, Chihota V, et al: The geographic diversity of
nontuberculous mycobacteria isolated from pulmonary samples: a
NTM-NET collaborative study. Eur Respir J 2013. Epub ahead of print,
doi: 10.1183/09031936.00149212.
23. van Ingen J, van der Laan T, Dekhuijzen R, Boeree M, van Soolingen D: In
vitro drug susceptibility of 2275 clinical non-tuberculous mycobacterium
isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010,
35(2):169–173.
24. Levy-Frebault VV, Portaels F: Proposed minimal standards for the genus
mycobacterium and for description of new slowly growing
mycobacterium species. Int J Syst Bacteriol 1992, 42(2):315–323.
25. Ferroni A, Vu-Thien H, Lanotte P, Le Bourgeois M, Sermet-Gaudelus I,
Fauroux B, Marchand S, Varaigne F, Berche P, Gaillard JL, et al: Value of the
chlorhexidine decontamination method for recovery of nontuberculous
mycobacteria from sputum samples of patients with cystic fibrosis. J Clin
Microbiol 2006, 44(6):2237–2239.
26. Tortoli E, Pecorari M, Fabio G, Messino M, Fabio A: Commercial DNA
probes for mycobacteria incorrectly identify a number of less frequently
encountered species. J Clin Microbiol 2010, 48(1):307–310.
27. van Ingen J, Boeree MJ, de Lange WC, de Haas PE, van der Zanden AG, Mijs
W, Rigouts L, Dekhuijzen PN, van Soolingen D: Mycobacterium
noviomagense sp. nov.; clinical relevance evaluated in 17 patients.
Int J Syst Evol Microbiol 2009, 59(Pt 4):845–849.
28. Petrini B: Mycobacterium abscessus: an emerging rapid-growing
potential pathogen. APMIS 2006, 114(5):319–328.
29. Van Ingen J: Nontuberculosis Mycobacteria; from gene sequence to clinical
relevance. Thesis. Nijmegen: Univerity of Nijmegen; 2009.
30. Tortoli E: Impact of genotypic studies on mycobacterial taxonomy: the
new mycobacteria of the 1990s. Clin Microbiol Rev 2003, 16(2):319–354.
31. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH: Clinical
significance of nontuberculous mycobacteria isolated from respiratory
specimens in Korea. Chest 2006, 129(2):341–348.
32. Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P,
Sorensen HT, Lescure FX, Thomsen RW: Nontuberculous pulmonary
mycobacteriosis in Denmark: incidence and prognostic factors. Am J
Respir Crit Care Med 2010, 181(5):514–521.
33. Clinical and Laboratory Standards Institute: Susceptibility testing of
mycobacteria, Nocardia, and other aerobic actinomycetes. Secondth edition.
Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI document
M24-A2.
doi:10.1186/1471-2334-14-62
Cite this article as: van der Werf et al.: Inventory study of non-tuberculous
mycobacteria in the European Union. BMC Infectious Diseases 2014 14:62.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Werf et al. BMC Infectious Diseases 2014, 14:62 Page 9 of 9
http://www.biomedcentral.com/1471-2334/14/62
